New drug combo takes on advanced cancers in early human test
NCT ID NCT05701527
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called EBC-129, both by itself and together with the immunotherapy pembrolizumab, in people with advanced solid tumours that have stopped responding to standard treatments. The study will enroll about 98 adults and focus mainly on safety, side effects, and finding the right dose. Researchers will also look for early signs of tumour shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EBC-129 (an experimental drug) and pembrolizumab (an immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumours who have run out of standard therapies.
What could go wrong
This is an early Phase 1 trial with only 98 participants, so the main goal is safety, not effectiveness. The drug may not shrink tumours or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Centre Singapore
RECRUITINGSingapore, South West, 168583, Singapore
Contact
-
National University Hospital - Medical Oncology
RECRUITINGSingapore, South West, 119228, Singapore
Contact
-
Taipei Veterans General Hospital
NOT_YET_RECRUITINGTaipei, Taipei, 11217, Taiwan
-
UT MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center
RECRUITINGAurora, Colorado, 80045-2517, United States
Contact